These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1622175)

  • 21. Fleroxacin pharmacokinetics in healthy volunteers and impaired renal function.
    Höffler D; Koeppe P; Metz R; Pech M; Sörgel F
    J Chemother; 1989 Jul; 1(4 Suppl):558-60. PubMed ID: 16312531
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers.
    Lubowski TJ; Nightingale CH; Sweeney K; Quintiliani R
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2758-60. PubMed ID: 1482143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
    Gentilini P; La Villa G; Marra F; Carloni V; Melani L; Foschi M; Cotrozzi G; Quartini M; Chibbaro G; Tommasi AC; Bernareggi A; Simoni A; Buzzelli G; Laffi G
    J Hepatol; 1996 Oct; 25(4):481-90. PubMed ID: 8912147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Furosemide kinetics in patients with hepatic cirrhosis with ascites.
    Fuller R; Hoppel C; Ingalls ST
    Clin Pharmacol Ther; 1981 Oct; 30(4):461-7. PubMed ID: 7285480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers.
    Orlando R; Floreani M; Padrini R; Palatini P
    Br J Clin Pharmacol; 1998 Dec; 46(6):605-9. PubMed ID: 9862251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of fleroxacin determined by biological method.
    Verbist L; Van Hecken A; De Schepper P
    J Chemother; 1989 Jul; 1(4 Suppl):572-3. PubMed ID: 16312537
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetics of fleroxacin in horses.
    Rebuelto M; Otero P; Albarellos G; Ambros L; Kreil V; Waxman S; Montoya L; Hallu R
    J Vet Pharmacol Ther; 2000 Apr; 23(2):103-5. PubMed ID: 10849255
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
    Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
    Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
    Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overview of the pharmacokinetics of fleroxacin.
    Nightingale CH
    Am J Med; 1993 Mar; 94(3A):38S-43S. PubMed ID: 8452184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.
    Fischman AJ; Livni E; Babich J; Alpert NM; Liu YY; Thom E; Cleeland R; Prosser BL; Callahan RJ; Correia JA
    Antimicrob Agents Chemother; 1992 Oct; 36(10):2286-92. PubMed ID: 1444310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide in patients with cirrhosis.
    Schwartz S; Brater DC; Pound D; Green PK; Kramer WG; Rudy D
    Clin Pharmacol Ther; 1993 Jul; 54(1):90-7. PubMed ID: 8330470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
    Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
    Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.
    Fischman AJ; Livni E; Babich J; Alpert NM; Liu YY; Thom E; Cleeland R; Prosser BL; Correia JA; Strauss HW
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2144-52. PubMed ID: 8257137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
    Wensing G; Hoffmann K; Heidemann HT
    Z Gastroenterol; 1993 Jan; 31(1):15-9. PubMed ID: 8447150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of encainide in patients with cirrhosis.
    Wensing G; Mönig H; Ohnhaus EE; Hoensch HP
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):733-9. PubMed ID: 1909559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of hepatic disease on the disposition of moricizine in humans.
    Pieniaszek HJ; Davidson AF; McEntegart CM; Quon CY; Sampliner RE; Mayersohn M
    Biopharm Drug Dispos; 1994 Apr; 15(3):243-52. PubMed ID: 7880984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
    Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in patients with hepatic cirrhosis.
    Hayton WL; Kneer J; Blouin RA; Stoeckel K
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1318-22. PubMed ID: 2386364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism of fleroxacin in man.
    Sörgel F; Seelmann R; Naber K; Metz R; Muth P
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():169-78. PubMed ID: 3144535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.